Anastasis Biotec — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Anastasis Biotec is an early-stage, private biotech focused on a precision oncology strategy that matches specific cancer-driving mutations with proprietary pathway inhibitors. The company is in the pre-clinical development stage, having raised initial funding through equity crowdfunding to advance its R&D and support external research collaborations. Its goal is to provide a tailored treatment for cancers with significant unmet need, with clinical efficacy data anticipated in four to five years.

Oncology

Technology Platform

Precision oncology platform that matches proprietary pathway inhibitors to specific cancer-driving mutations identified in patient tumor biopsies, with an aim to target cancer stem cells.

Opportunities

The precision oncology market is large and growing, with a high demand for therapies targeting specific mutations and cancer stem cells to address treatment resistance.

A successful demonstration of efficacy could lead to lucrative partnerships or acquisition by a larger pharmaceutical company.

Risk Factors

The company is at a very early, high-risk pre-clinical stage with unproven technology and relies on modest crowdfunding, which may be insufficient for costly drug development.

The scientific approach of targeting cancer stem cells and specific pathways like Notch is biologically complex and competitively crowded.

Competitive Landscape

Anastasis operates in the highly competitive precision oncology field, competing with numerous biotech and pharmaceutical companies developing targeted therapies and cancer stem cell inhibitors. Its undisclosed compounds will need to demonstrate significant differentiation in efficacy or safety to capture market share.

More companies in United Kingdom →